Skip to main content
. Author manuscript; available in PMC: 2011 Feb 3.
Published in final edited form as: Vaccine. 2009 Nov 24;28(5):1363. doi: 10.1016/j.vaccine.2009.11.005

Figure 1.

Figure 1

Cox-2 deficient mice have impaired VV-specific IgG responses. Wild-type and Cox-2−/− mice were infected with 1×106 PFU VV (n = 4). VV-specific IgG2a antibody titers (plasma) were assessed by ELISA 28 days after infection. (A) IgG2a antibody titers were significantly reduced in Cox-2 −/− mice (open triangles) compared to wild-type mice (closed circles). (B) The presence of neutralizing antibody titers in wild-type and Cox-2−/− plasma was assessed by plaque assay. VV was incubated with dilutions (10−2, 5−2, 10−3, 15−3, 20−3, 25−3) of plasma and cultured with 143B fibroblasts for 48 hours. The percent reduction of plaques in the presence of plasma compared to no plasma controls is shown. Bone marrow cells were assessed for VV-specific antibody secreting cells on day 28 by ELISPOT. (C) Numbers of IgM, IgG1, IgG2a, IgG2b or IgG3 secreting cells in wild-type (black) and Cox-−/− (gray) mice are shown. (D) The average spot size for each isotype is also shown. Data are represented as mean ± SEM, * p <0.05.